Holen Sie sich die Stockscreener-App
1.65
5.17%
-0.09
Vorhandelsmarkt:
1.65
Schlusskurs vom Vortag:
$1.74
Offen:
$1.8
24-Stunden-Volumen:
560.29K
Relative Volume:
0.58
Marktkapitalisierung:
$87.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-151.16M
KGV:
-0.5556
EPS:
-2.97
Netto-Cashflow:
$-130.08M
1W Leistung:
+3.77%
1M Leistung:
+1.85%
6M Leistung:
-73.17%
1J Leistung:
-87.60%
1-Tages-Spanne:
$1.6301
$1.80
1-Wochen-Bereich:
$1.56
$1.80
52-Wochen-Spanne:
$1.19
$17.82
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Firmenname
Alx Oncology Holdings Inc
Sektor
Branche
Telefon
650-466-7125
Adresse
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALXO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.65 | 87.03M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2024-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-12-22 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-06 | Eingeleitet | UBS | Buy |
| 2021-02-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-11 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-11 | Eingeleitet | Jefferies | Buy |
| 2020-08-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Alx Oncology Holdings Inc Aktie (ALXO) Neueste Nachrichten
ALX Oncology to Host Virtual Company Event Highlighting - GlobeNewswire
ALX Oncology to Present Crucial Evorpacept Cancer Trial Data at ASCO GI Symposium - StockTitan
ALX Oncology launches new equity incentive plan - MSN
ALX Oncology launches new equity incentive plan By Investing.com - Investing.com South Africa
ALX Oncology Adopts 2025 Inducement Equity Plan - TipRanks
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Down 9.4% in December - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Jane Street Group LLC Trims Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
Barclays PLC Buys 42,185 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
3 US Penny Stocks With Market Caps Under $100M To Watch - Yahoo Finance
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
State Street Corp Trims Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
Alx oncology interim CFO Pinto sells $2,253 in stock By Investing.com - Investing.com Australia
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 10,796 Shares - MarketBeat
Alx Oncology president sells $17,059 in stock By Investing.com - Investing.com Nigeria
Alx Oncology president sells $17,059 in stock - Investing.com
Alx oncology interim CFO Pinto sells $2,253 in stock - Investing.com
Bicara’s era? Merus, ALX also active in head and neck cancer - BioWorld Online
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Up 17.0% in December - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Large Increase in Short Interest - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Jefferies Financial Group Downgrades ALX Oncology (NASDAQ:ALXO) to Hold - Defense World
ALX Oncology’s (ALXO) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World
ALX Oncology’s (ALXO) “Buy” Rating Reiterated at HC Wainwright - Defense World
Alx Oncology Holdings Inc (ALXO) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
ALX Oncology falls as Jefferies cuts on lead cancer drug - MSN
ALX Oncology stock falls on Jefferies downgrade (ALXO:NASDAQ) - Seeking Alpha
Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold' - Investing.com Canada
ALX Oncology (NASDAQ:ALXO) Rating Lowered to Hold at Jefferies Financial Group - MarketBeat
ALX Oncology shares target steady, hold rating on positive clinical results - Investing.com Canada
Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines - Baystreet.ca
ALX Oncology (NASDAQ:ALXO) Earns "Overweight" Rating from Cantor Fitzgerald - MarketBeat
HC Wainwright Reiterates Buy Rating for ALX Oncology (NASDAQ:ALXO) - MarketBeat
ALX Oncology to Present Updated Results from Phase 2 - GlobeNewswire
ALX Oncology to Present Key Phase 2 Gastric Cancer Trial Data at ASCO GI 2025 Symposium - StockTitan
Verition Fund Management LLC Acquires 100,454 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology Highlights Promising Trial Results - MSN
ALX Oncology to Host Webcast on December 17 Featuring Phase 1b/2 Trial Data for Evorpacept in Metastatic Breast Cancer - Nasdaq
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 - The Manila Times
ALX Oncology Sets Key Data Review: Evorpacept Breast Cancer Trial Results From SABCS 2024 - StockTitan
Fmr LLC Sells 1,949,890 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - MarketBeat
Finanzdaten der Alx Oncology Holdings Inc-Aktie (ALXO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alx Oncology Holdings Inc-Aktie (ALXO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pinto Shelly | Interim CFO |
Dec 30 '24 |
Sale |
1.58 |
1,426 |
2,253 |
90,123 |
| Pons Jaume | PRESIDENT & CSO |
Dec 30 '24 |
Sale |
1.58 |
10,796 |
17,060 |
580,714 |
| Hemrajani Rekha | Director |
Dec 02 '24 |
Buy |
1.55 |
30,000 |
46,404 |
33,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 14 '24 |
Sale |
2.58 |
564 |
1,455 |
91,549 |
| Randolph Sophia | CHIEF MEDICAL OFFICER |
Aug 14 '24 |
Sale |
2.58 |
1,365 |
3,522 |
325,711 |
| Pons Jaume | PRESIDENT & CSO |
Aug 14 '24 |
Sale |
2.58 |
1,937 |
4,997 |
591,510 |
| Pons Jaume | PRESIDENT & CSO |
Jul 11 '24 |
Option Exercise |
0.99 |
20,000 |
19,800 |
613,447 |
| Pons Jaume | PRESIDENT & CSO |
Jul 11 '24 |
Sale |
7.90 |
20,000 |
158,076 |
593,447 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 05 '24 |
Sale |
5.50 |
1,823 |
10,025 |
92,113 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 01 '24 |
Sale |
5.82 |
1,373 |
7,989 |
93,936 |
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):